[Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Lee HW;Lee HW
  • Source:
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi [Korean J Gastroenterol] 2019 Nov 25; Vol. 74 (5), pp. 251-257.
  • Publication Type:
    Journal Article; Review
  • Language:
    Korean
  • Additional Information
    • Source:
      Publisher: Korean Society of Gastroenterology Country of Publication: Korea (South) NLM ID: 101189416 Publication Model: Print Cited Medium: Internet ISSN: 2233-6869 (Electronic) Linking ISSN: 15989992 NLM ISO Abbreviation: Korean J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Seoul, Korea : Korean Society of Gastroenterology, [2003]-
    • Subject Terms:
      Antiviral Agents/*therapeutic use ; Carcinoma, Hepatocellular/*pathology ; Hepatitis B, Chronic/*drug therapy ; Liver Neoplasms/*pathology; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/mortality ; Guanine/analogs & derivatives ; Guanine/therapeutic use ; Humans ; Incidence ; Liver Neoplasms/ethnology ; Liver Neoplasms/mortality ; Proportional Hazards Models ; Tenofovir/therapeutic use ; Treatment Outcome
    • Abstract:
      Multiple studies have shown that oral antiviral therapies reduced the incidence of hepatocellular carcinoma (HCC) and improved the survival of patients with chronic hepatitis B when compared with that of untreated patients. In particular, entecavir and tenofovir share the qualities of high efficacy in reducing the HBV DNA levels, and they have excellent tolerability and safety. These drugs modified the natural history of liver fibrosis, improve liver function, decrease the incidence of HCC, decrease the need for liver transplantation, and improve survival. Many studies have suggested that long-term antiviral therapy reduces the risk of HCC and liver cirrhosis in patients with chronic hepatitis. The mechanism of these drugs in reducing the risk of HCC is not clear. This article reviews the mechanisms of carcinogenic HBV by conducting a review of the literature on the efficacy of therapy for reducing the risk of HCC. A few recent articles have suggested that tenofovir offers advantages over entecavir in terms of HCC prevention, but these articles have the inherent limitations of observational data. No other head-to-head randomized trials exist. Further randomized studies would help provide stronger evidence of the association between the type of antiviral agent and the HCC outcomes. Only achieving complete viral eradication from the liver will truly decrease the mortality and incidence of HCC.
    • Contributed Indexing:
      Keywords: Antiviral agents; Carcinoma; Hepatitis B; Mortality; chronic; hepatocellular
    • Accession Number:
      0 (Antiviral Agents)
      5968Y6H45M (entecavir)
      5Z93L87A1R (Guanine)
      99YXE507IL (Tenofovir)
    • Publication Date:
      Date Created: 20191126 Date Completed: 20200515 Latest Revision: 20200515
    • Publication Date:
      20250114
    • Accession Number:
      10.4166/kjg.2019.74.5.251
    • Accession Number:
      31765553